MSH2 and breast carcinoma: There may be a very modest risk of breast cancer (10 years risk 2% [95% CI = 1–4%]; SIR = 1.76 [95% CI = 1.07–2.59]) following CRC among women with MMR gene mutations; however, the majority of the MMR genes in the report were MSH2 and MLH1 (both thought to be associated with greater cancer risk) (98).